|Description||LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.|
|B0084-307751||50 mg||$199||In stock|
|Related CAS||1062368-62-0 (HCl); 1435934-00-1 (dihydrochloride)|
|Synonyms||4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline; LDN193189; LDN 193189; LDN-193189|
ALK inhibitor 2
ALK inhibitor 2 is a novel and selective inhibitor for the ALK kinase.
Lorlatinib is an ATP-competitive ROS1/ALK inhibitor with potential antitumor activity. Lorlatinib binds to both ALK and ROS1 kinases, resulting in disruption of...
LDN 212854 trihydrochloride is a hydrochloride salt form of LDN 212854, which is a potent ALK2-biased BMP type I receptor kinase inhibitor (IC50 values 2.4 nM, ...
LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2. LDN-212854 exhibits some selectivity for ALK2 in preference to other...
R-268712 is a potent and selective inhibitor of TGF-β type I receptor/ALK5 with an IC50 of 2.5 nM, an approximately 5000-fold more selectivity for ALK5 than p38...
CH5424802 Hcl (AF 802 Hcl; Alectinib Hcl) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.
Brigatinib, is an orally active, also known as AP-26113, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase(ALK belongs to t...
BAY-754 is an ALK-1 inhibitor used as an anti-angiogenesis agent. It inhibited the eye vascular leakage in dose manner in mouse model.
SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptor ALK5 and as well as being a selective inhibitor of ALK4 but with less pote...
Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2.
LDN193189 is a selective and potent ALK inhibitor with potential anticancer activity.
K02288 is a highly selective 2-aminopyridinebased inhibitor K02288 with in vitro activity against ALK2 at low nanomolar concentrations similar to the current le...
HG-14-10-04 is a potent and specific ALK inhibitor with IC50 of 20 nM.
IN-1130 is a selective ALK5 inhibitor with >100 fold selectivity over p38α and a panel of 26 other serine/threonine and tyrosine kinases. It also inhibit phosph...
AP26113 is an orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) with pote...
CEP-28122 is a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers...
Alectinib, also known as AF802, or CH5424802 or RO5424802, is a potent, selective, and orally available ALK inhibitor with a unique chemical scaffold, showing ...
LDN193189 HCl is the hydrochloride salt of LDN193189, which is a selective BMP signaling inhibitor, and inhibits the transcriptional activity of the BMP type I ...
CEP-37440 is an orally available dual kinase inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and focal adhesion kinase (FAK), with po...
Ceritinib, also known as LDK378, is a selective inhibitor of ALK1, a target found in metastatic non-small cell lung cancer (NSCLC). In Phase I trials, LDK378 s...